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Abstract 
Background: Primary HIV-associated thrombocytopenia (PHAT) typically improves with highly active antiretrovi-
ral therapy (HAART); however, cases continue to occur. Data comparing the epidemiology of PHAT between the 
pre-HAART and HAART eras are limited. We retrospectively examined the incidence of PHAT over 28 years in the US 
Military HIV Natural History Study (NHS) from 1986 to 2013.
Results: Subjects had a nadir platelet count <100 × 109/l with no other identifiable cause. Time periods were 
categorized as pre-HAART (1986–1995), early HAART (1996–2001), and later HAART (2002–2013). Incidence, demo-
graphic data, and CD4 count were compared across the three eras. A generalized estimating equations model was 
used to assess any association of platelet count and HIV viral load in cases diagnosed during the HAART eras. 218 par-
ticipants met the case definition. 86.2 % of cases occurred prior to 2002. The incidence of PHAT per 1000 person-years 
of follow-up was 16.3, 4.6, and 1.9 during pre-HAART, early HAART and later HAART eras respectively. CD4 cell counts 
were significantly higher in the HAART eras at the time of thrombocytopenia (p < 0.001). Of patients diagnosed after 
1996, 96.4 % were viremic within six months preceding the platelet nadir and over half were antiretroviral naïve. Viral 
load (per log10 copies/ml) inversely correlated with platelet count throughout the HAART eras (p < 0.0001).
Conclusions: The incidence of PHAT has markedly decreased in the HAART era. However, viremic individuals, includ-
ing those with healthy CD4 cell counts, may be at risk. Achieving viral suppression as early as possible may decrease 
the incidence further.
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Research hypothesis
The incidence and characteristics of primary HIV-associ-
ated thrombocytopenia have changed in the era of highly 
active antiretroviral therapy.
Background
Thrombocytopenia, in the absence of secondary causes 
(e.g. drugs, opportunistic infections, malignancy), has 
been observed in HIV-infected persons since the begin-
ning of the epidemic [1]. Primary HIV-associated 
thrombocytopenia (PHAT) may occur at any stage of 
HIV disease. In the early stages of infection, the clini-
cal picture may be identical to immune thrombocytope-
nia purpura (ITP) with accelerated platelet destruction 
related to immune complexes and cross-reacting platelet 
antibodies [2]. As HIV disease progresses, thrombocy-
topenia may develop by other virus-related mechanisms 
including suppression of platelet replication, shortening 
of platelet life span, and direct destruction of megakaryo-
cytes [3, 4].
PHAT typically improves with highly active antiretro-
viral therapy (HAART) [5–7]. However, cases continue 
to be observed. Although it is generally presumed that 
the incidence declined from the pre-HAART era, data 
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comparing the pre-HAART and HAART eras are limited 
[8]. Understanding the effect of HAART on the epidemi-
ology of PHAT may have implications regarding the tim-
ing of HAART initiation. In this study, we examined the 
change of incidence and characteristics of PHAT from 
the pre-HAART to HAART era in a US military popula-
tion from 1986 to 2013. We also examined the relation-
ship of thrombocytopenia with HIV viral load and CD4 
count.
Methods
The US Military HIV Natural History Study (NHS) is an 
ongoing, continuous enrollment observational cohort 
of Department of Defense active duty and beneficiar-
ies diagnosed with HIV infection, followed at six mili-
tary medical centers in the United States and has been 
previously described [9]. Enrolling since 1986, the NHS 
has approximately 5700 participants with signed writ-
ten consent. Approval for this research was obtained by 
the Ethics Committees of the Uniformed Services Uni-
versity of the Health Sciences, Bethesda, MD and each 
participating site (San Antonio Military Medical Center, 
Fort Sam Houston, TX, Walter Reed National Military 
Medical Center, Bethesda, MD, Naval Medical Center 
Portsmouth, Portsmouth, VA, Naval Medical Center San 
Diego, San Diego, CA, Tripler Army Medical Center, 
Honolulu, HI, and Madigan Army Medical Center, 
Tacoma, WA).
Following enrollment, subjects have study visits 
approximately every 6  months. Data collected at each 
visit include demographic information, past and interim 
medical histories and illnesses, medications, vaccina-
tions, and standard clinical laboratory studies, including 
annual screening for hepatitis B and C viruses. Due to 
prior Department of Defense policy (“Don’t Ask, Don’t 
Tell”), HIV exposure category has not been routinely cap-
tured for the majority of the study visit. However, rates 
of HIV risk behaviors have been previously reported and 
intravenous drug use is rare (<3 %) [10].
Data from the NHS was retrospectively analyzed 
from 1986 to 2013. Cases were identified as those sub-
jects who received a diagnostic code for ITP (defined as 
thrombocytopenia <150 × 109/l on at least two consecu-
tive occasions and a nadir platelet count  <100  ×  109/l, 
and no other secondary causes including drugs and 
opportunistic infection were identified). Subjects ini-
tially diagnosed with ITP were excluded if they were 
coinfected with hepatitis B or C or subsequently found 
to have cirrhosis, leukemia, or solid tumor malignancy 
with exception of non-melanoma skin cancer. This defi-
nition is consistent with that recommended by an ITP 
International Working Group of recognized experts 
[11]. For this study, we elected to use the term “primary 
HIV-associated thrombocytopenia” in recognition that 
immune and nonimmune mechanisms may be involved. 
Variables included demographics (age, gender, race), 
platelet counts, CD4 cell count and HIV viral load within 
6 months preceding the nadir platelet count. Time peri-
ods were classified as pre-HAART (1986–1995), early 
HAART (1996–2001), and later HAART (2002–2013). 
Person-years of follow-up (PYFU) for each subject was 
measured as the time from the documented date of sero-
positivity to the time of last visit or established diagnosis 
of PHAT, whichever occurred first.
Comparisons were made between the three eras in 
incidence of primary HIV-associated thrombocytope-
nia (cases per 1000 person-years of follow-up), age, race, 
gender, and CD4 cell count and HIV viral load within 
6 months preceding the platelet nadir. Descriptive statis-
tics utilized Chi squared test for categorical variables and 
Kruskal–Wallis test for continuous variables. A general-
ized estimating equations model was used to assess any 
association between HIV viral load and platelet count in 
patients diagnosed with PHAT during the HAART eras.
Results
5697 subjects enrolled in NHS from 1986 to 2013. 
Of these, 3231 enrolled during the pre-HAART era 
(1986–1995), 955 enrolled during the early HAART era 
(1996–2001), and 1551 enrolled during later HAART era 
(2002–2013). PYFU during each time period was 9282 
(pre-HAART era), 8005 (early HAART era), and 16,150 
(later HAART era). 218 participants met the case defini-
tion of PHAT (Table 1).
The majority of cases (86.2 %) occurred prior to 2002. 
The incidence per 1000 PYFU markedly decreased over 
time with a rate of 16.3, 4.6, and 1.9 during the pre-
HAART, early HAART and later HAART eras respec-
tively (p  <  0.001). Platelet count was more likely to fall 
below 50 × 109/l in the pre-HAART era (odds ratio 2.75, 
95 % confidence interval 1.46–5.20, p = 0.002). However, 
the proportion of cases in which the platelet count nadir 
was less than 20 × 109/l did not significantly differ across 
the three eras.
CD4 cell count within 6  months prior to the plate-
let nadir was recorded in 216 participants and progres-
sively shifted to higher values over the three eras. In the 
pre-HAART era, CD4 cell counts were ≤200 cells/μl in 
52.3 % of the thrombocytopenic cases compared to 40.5 
and 10 % in the early and later HAART eras respectively. 
The proportion of subjects with CD4 cell counts above 
350 cells/μl were similar in the pre-HAART (29.8 %) and 
early HAART (27.8 %) eras but was higher (56.7 %) dur-
ing the later HAART era.
Of the 67 patients who became thrombocyto-
penic during the HAART eras, 37 (55.2  %) were 
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antiretroviral-naïve. This included 11 of 15 cases where 
the CD4 count was  >500 cells/μl. Laboratory data in 
which HIV viral load was recorded within 6 months pre-
ceding the nadir platelet count was available in 56 sub-
jects. Of these, HIV viremia was detected in 54 (96.4 %) 
participants, of whom 29 (53.7  %) had not previously 
received antiretroviral therapy. Median (IQR) viral load 
prior to the platelet nadir was 32,531 (4473, 78,385) 
copies/ml.
All platelet counts and HIV viral load assays which were 
drawn simultaneously from 1996 to 2013 were studied 
among subjects diagnosed with PHAT at any time during 
the HAART era. This included 1009 data points in 63 sub-
jects and showed a strong association between time updated 
viral load per log10 copies/ml and platelet count. This rela-
tionship was highly significant (p < 0.0001) using a general-
ized estimating equation model. Each rise in one viral load 
log10 corresponded with a decline of 19 × 109/l platelets.
Discussion
In our US military cohort, the incidence of PHAT 
declined approximately eight-fold after 2001 compared 
to the pre-HAART era. Cases diagnosed during the 
HAART era were characterized by significantly higher 
CD4 cell counts. In cases where recent viral load data was 
available, we found that nearly all cases diagnosed in the 
HAART era coincided with detectable HIV viremia. Our 
study is consistent with other reports showing a strong 
correlation between viral load and platelet count in HIV-
associated thrombocytopenic patients [5–7, 12].
Prior to the advent of HAART, thrombocytopenia, 
defined as platelet count  <150,000  ×  109/l, was identi-
fied in 10–30  % of HIV-infected patients with the inci-
dence increasing with progression of disease [13]. In 
the HAART era, several studies have found an inci-
dence of 10–15  %, using the same cut-off value [13]. In 
a recent retrospective study of a large Italian cohort, 
severe thrombocytopenia (<50 × 109/l) developed in 597 
of 5137 subjects from 1985 to 2012, with the incidence 
declining over time from 63.4/1000 PYFU (1985–1989) 
to 14.9/1000 PYFU in the HAART era (1997–2012) [14]. 
Studies of thrombocytopenia in HIV-infected patients 
vary in case definition, inclusion of secondary causes, 
coinfections, or focus on clinical features and outcome. 
For instance, in the Italian cohort, 44.4 % of the subjects 
were seropositive for hepatitis C virus (HCV), 34 % had 
chronic liver disease and 14.7  % were diagnosed with 
malignancy. Thus, only 35 of the reported cases over a 
28 year period could be classified as primary HIV-related 
thrombocytopenia [14].
Because of the unique features of our cohort, we 
focused our study on cases of thrombocytopenia where 
Table 1 Characteristics of subjects diagnosed with primary HIV-associated thrombocytopenia in the US Military Natural 
History Study 1986–2013








No. of cases 151 37 30
Median age (yrs) (IQR) 32 (27, 38) 34 (31, 39) 36 (29, 41) NS
Male gender 138 (91.4 %) 36 (97.3 %) 30 (93.3 %) NS
Race NS
 Caucasian 87 (57.6 %) 25 (67.6 %) 17 (56.7 %)
 African–American 52 (34.4 %) 9 (24.3 %) 10 (33.3 %)
 Hispanic 10 (6.6 %) 2 (5.4 %) 2 (6.7 %)
 Other 2 (1.4 %) 1 (2.7 %) 1 (3.3 %)
Nadir platelet count
 <50 × 109/l 73 (48.3 %) 11 (29.7 %) 6 (20.0 %) 0.005
 <20 × 109/l 33 (21.8 %) 6 (16.2 %) 4 (13.3 %) NS
CD4 count (cells/μl)
 ≤100 59 (39.1 %) 9 (24.3 %) 2 (6.7 %)
 101–200 20 (13.2 %) 6 (16.2 %) 1 (3.3 %)
 201–350 26 (17.2 %) 11 (29.7 %) 10 (33.3 %)
 351–500 19 (12.6 %) 4 (10.8 %) 8 (26.7 %)
 >500 26 (17.2 %) 6 (16.2 %) 9 (30.0 %)
 Not determined 1 (0.7 %) 1 (2.7 %)
 Median (IQR) 156 (30, 406) 262 (148, 378) 380 (255, 517) <0.001
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HIV infection was the only identifiable predisposing 
factor. Our subjects have free access to health care and 
low incidence of intravenous drug abuse. Because of 
mandatory screening for HIV infection in the US mili-
tary, most of our subjects enroll in the cohort early in 
the course of HIV infection, while in relatively good 
health. Our participants are screened yearly for hepa-
titis B and C viruses. Because HCV serology was not 
available prior to 1990, negative antibody testing could 
not be recorded in 28 of our PHAT cases in the pre-
HAART era. These included 23 subjects born between 
1945 and 1965, the birth cohort with highest prevalence 
of HCV infection. Although these persons did not have 
risk factors for HCV or signs of liver disease, we recog-
nize the possibility that some of these cases may have 
had undiagnosed HCV co-infection. However, we do 
not feel this would change our results significantly. Had 
all 28 subjects been excluded from analysis, the pre-
HAART incidence would have dropped from 16.3 to 
13.3 cases/1000 PYFU and a seven-fold reduction in the 
later HAART era.
Although our results may not be representative of other 
HIV-infected populations, fewer confounding variables 
found in NHS subjects may allow clearer distinction of 
cases of primary HIV-associated thrombocytopenia and 
more accurate analysis of the longitudinal changes in epi-
demiology associated with the HAART eras. In contrast 
to thrombocytopenia more commonly present in persons 
with late stage HIV disease prior to the HAART era, the 
majority of cases in the later HAART era were associated 
with CD4 cell counts >350 cells/μl. Furthermore, almost 
all of the cases diagnosed after 1996 had detectable HIV 
viremia. These results are similar to a study of 73 HIV-
infected thrombocytopenic (<100  ×  109/l) patients in 
New York City where HIV viremia was detected in 21 
of 22 subjects without HCV or cirrhosis [15]. More than 
half of our subjects with thrombocytopenia after 1996 
were HAART-naïve, consistent with HAART initia-
tion guidelines at the time based on their CD4 cell lev-
els. Our study is limited by its retrospective nature and 
under-representation of women. Clinical presentation 
and treatment of thrombocytopenia were not included in 
the design.
In conclusion, the HAART era has had a marked effect 
on the incidence of PHAT, although viremic individuals, 
including those with healthy CD4 cell counts, may be at 
risk. Further decline in incidence may be another poten-
tial benefit to beginning HAART as early as possible [16].
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